Response Rate of Ifosfamide Plus Cisplatin and Etopside for Previously Treated Recurrent Small Cell Lung Cancer

This study was undertaken to determine the activity and toxicity of ifosfamide plus cisplatin and etopodide regimens (VIP) for previously treated recurrent small cell lung cancer.39 patients were assessable for response and toxicity.Main combination chemotherapy regimens,the patients had received previously were PE and CE.In this study,these patients received 2 3 courses of VIP.22 of 39 patients had an objective response,including 2 CR and 20 PR.Compared with PE、CE regimens,the main toxicity of VIP was myelosuppressioin and mild gastrointestinal reaction.We think that ifosfamide plus cisplatin and etopodide regiments (VIP) are an active regimen in the treatment of recurrent SCLC.But hematological toxicity was severe in these pretreated patients.